XORTX Therapeutics, Inc.

As of June 30, 2026, XORTX Therapeutics, Inc. carries a market capitalization of 5.54M, placing it among publicly traded companies globally. Its enterprise value stands at 4.13M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

XORTX Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, XORTX Therapeutics, Inc. has 1.73M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, XORTX Therapeutics, Inc. maintains a current ratio of 3.59, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, XORTX Therapeutics, Inc. posted a negative return on equity (ROE) of -99.24, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -83.78, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 3.00, a quick read on workforce productivity versus industry peers.

As of the close on August 31, 2026, XORTX Therapeutics, Inc.'s stock has declined approximately 42.52% over the past 52 weeks. The 50-day moving average sits at 3.16, while the 200-day moving average is 4.40.

Over the twelve months ended June 30, 2026, XORTX Therapeutics, Inc. generated - - in revenue and converted that into -5.31M in net income, yielding earnings per share of -4.01. EBITDA reached -5.41M, while operating income came in at -5.56M.

These figures are as of June 30, 2026. Total book value stands at 7.81M, with working capital of 2.49M providing operational flexibility.

XORTX Therapeutics, Inc. produced -7.24M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -251,757.92 in capital expenditures, free cash flow totaled -7.49M - equivalent to -5.66 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -176.87: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -139.84, meaning XORTX Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

XORTX Therapeutics, Inc.'s most recent stock split took place on April 6, 2026 with a 5:1 split ratio.

As of June 30, 2026, XORTX Therapeutics, Inc. has an Altman Z-Score of -9.66, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.